Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Nov 06, 2022 11:53am

218 Views

Post# 35077266

RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

PwC reiterates Big Pharma's M&A $5 billion to $15 billion range "sweet-spot" as detailed in PwC's October 2022 success factor report.

October 20, 2022 - "... many companies have recently spent significant time and effort transforming themselves to focus on core therapeutic areas and continued innovation.

With many companies facing patent and pipeline challenges in the 2024-28 period and the fact that biotech valuations appear to be rebalancing, the sweet spot these days for biotech deals appears to be in the $5 billion to $15 billion range."

<< Previous

Bullboard Posts

Next >>

Calibre discovers significant gold in Newfoundland